https://doi.org/10.4081/hmr.v3i1.540

Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 250
PDF: 448
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

YH Kim
support@pagepress.org
Zanolimumab (HuMax-CD4, Genmab, Copenhagen, Denmark) is a fully human monoclonal anti- CD4 antibody that targets the CD4 molecule on malignant Tcells in cutaneous T-cell lymphoma. Zanolimumab inhibits CD4+ T cells by combining signaling inhibition with antibody dependent cellular cytotoxicity (ADCC). T cell activation is inhibited by a fast dual mechanism in which the antibody abrogates signaling via the T cell receptor and, in addition, down regulates T cell activation by transmission of direct inhibitory signals. Zanolimumab induces killing of CD4+ T cells via ADCC by NK cells to which memory type (CD45RO+ CD4+) T cells are more sensitive than naïve (CD45RA CD4+) cells [Rider et al. Cancer Res 2007;67:9945-53] This latter observation may be of particular relevance for the treatment of cutaneous t-cell lymphoma (CTCL) which typically comprise CD45RO memory-type cells.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Kim, Y. (2009). Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.540
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).